肝血宝由浙江省中医药研究所负责研制,杭州前进制药厂生产,经著名血液病专家郁知非、洪宝源等九位教授主持通过鉴定,并经浙江省中医药研究所、北京医科大学附属人民医院、哈尔滨医科大学附属二院和三院、浙江医科大学附属一院及杭州肿瘤医院等18个医疗单位临床验证,治疗各种不同原因引起的白细胞减少症总有效率达88.6％,对肿瘤病人化疗、放疗所致的白细胞减少症总有效率达96.8％,为目前治疗白细胞减少症首选药物。 Hepaobao was developed by the Zhejiang Institute of Chinese Medicine and produced by the Hangzhou Advance Pharmaceutical Factory. It was certified by nine leading professors He Yifei and Hong Baoyuan, and was affiliated with the Institute of Traditional Chinese Medicine of Zhejiang Province and Beijing Medical University. People’s Hospital, Second Affiliated Hospital and Third Hospital of Harbin Medical University, First Affiliated Hospital of Zhejiang Medical University and Hangzhou Tumor Hospital have clinically verified that the total effective rate of leukopenia caused by various causes is 88.6%. The total effective rate of leukopenia caused by chemotherapy and radiotherapy for patients is 96.8%, which is currently the first choice for the treatment of leukopenia.